MAM
ST. Regis Mumbai welcomed its newly appointed hotel Manager Siddharth Sathe
Bringing in over a decade of experience in the hospitality sector, The St. Regis Mumbai had recently appointed Mr. Siddharth Sathe as Hotel Manager, and welcomed him to The St. Regis Mumbai’s ever-growing family. Having essayed roles in leading Indian and International chain of hotels, Siddharth commenced his career in the rooms division and moved on to head the F&B department with a keen sense of administration. This dual experience has equipped and enabled his rapid growth to the position of General Manager in a short span of time and his positively motivational approach is what earns him a nod of approval from one and all. As General Manager, Siddharth has honed his skills to have a bird’s eye perspective on all properties under his purview.
At The St. Regis Mumbai, Siddharth will focus on the revenue and reputation of the hotel focusing his activities on building the brand. Leading a dynamic operational team of over 400, he is optimistic about molding them to create exceptional moments for each guest. Honing them to focus on achieving high Guest Voice scores, paying attention to details for Brand Standard Audits, enhance Rooms Division Profitability and maximize operational productivity, he aims to work towards efficiency and consumer satiation.
Armed with a degree from the Institute of Hotel Management, Chennai and a post graduate degree from The Oberoi Centre of Learning & Development, Siddharth’s first role at a leading five star hotel chain laid out his strong foundation as a luxury hotelier. He has since, been a part of varied luxury properties within organizations like Marriott International and so on. With his keen business acumen and an overview of hotel operations, Siddharth has also been an integral part of the pre-opening team of a leading property in Srinagar and has also lead flagship properties with dedication and success.
A sports fanatic at heart, Siddharth enjoys relaxation with his family with cricket and golf topping the list of his favorites and he enjoys catching these games on or off the field when management is not on his mind.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
